__
AMRI (NASDAQ: AMRI) has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI’s Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.
Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
Service providers of every size and type are choosing Brocade (Nasdaq:BRCD) solutions to develop networks that deliver increasingly advanced combinations of voice, data, video and mobility (quad-play) services to businesses and consumers. These providers list reliability, low total cost of ownership (TCO) and a collaborative relationship as fundamental reasons for working with Brocade as their network provider of choice.
Morgan Stanley (NYSE: MS) today reported income of $1.4 billion, or $0.80 per diluted share, from continuing operations applicable to Morgan Stanley for the quarter ended June 30, 2010 compared with a loss of $138 million, or $1.36 per diluted share, for the same period a year ago. Net revenues were $8.0 billion for the current quarter compared with $5.2 billion a year ago. Net revenues in the current quarter included positive revenue of $750 million compared with negative revenue of $2.3 billion in the prior year’s second quarter related to Morgan Stanley’s debt-related credit spreads (DVA).1, 2 Comparisons of current quarter results with the prior year were affected by the results of Morgan Stanley Smith Barney (MSSB),3 which closed on May 31, 2009. The results for the quarter also included a tax benefit of $345 million, or $0.20 per diluted share, associated with the remeasurement of tax reserves based on the status of federal and state examinations. The annualized return on average common equity from continuing operations was 12.2% in the quarter.
Crown Equity Holdings, Inc. (OTCBB: CRWE) recently reported that it will implement a forward stock split of its common stock on a one-for-ten basis. In connection with this forward split, the Company will increase its authorized shares from 500,000,000 to 1,000,000,000 shares. An effective date for the split has not been determined but is expected to occur in late July for shareholders of record as of July 15, 2010. Ken Bosket, CEO of Crown Equity Holdings, Inc., stated, “It has been determined that this 1 - 10 forward split should benefit our shareholders by increasing the amount of liquidity available to investors therefore giving us the potential to attract more buyers of an institutional nature. Considering the huge increase in income Crown Equity Holdings, Inc. has experienced this past year, we are confident our future projected revenue stream will more than support this financial strategy.”
The GEO Group (NYSE: GEO) (“GEO”) reported that it has signed a contract with the State of Georgia, Department of Corrections for the development and operation of a new 1,500-bed correctional facility (the “Facility”) to be located in Milledgeville, Georgia.
**************************************************************
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).
.png)
.png)
.png)
